The purpose of this modification is to fund option year two (2) clin 2201 cgmp adjuvant: clinical or commercial scale bulk lot(s). QTY of 1 for unit price of $8,609,815. The period of performance…
Ended Awarded Last action
- Contract number
- 75A50120F33013
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $63,883
Award facts
- Contract value 100% obligated
- $63,882.74 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27709, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$1,692 | |
| Supplemental Agreement for work within scope | $31,476 | |
| Original award | $34,099 |
About this award
This is a modification to a delivery order contract awarded to GlaxoSmithKline, LLC, a foreign-owned, for-profit pharmaceutical company, by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response. The purpose of this modification is to fund Option Year Two of CLIN 2201, which is for CGMP (Current Good Manufacturing Practice) adjuvant production, either at the clinical or commercial scale, with a quantity of 1 and a unit price of $8,609,815. The overall contract has a ceiling value of $63,882.74 and a period of performance from August 22, 2020, through February 21, 2022. This contract is not set aside and is a firm-fixed-price delivery order. It is part of the broader Pandemic Influenza Preparedness and Response 2016-2021 contract vehicle.
Description
The purpose of this modification is to fund option year two (2) clin 2201 cgmp adjuvant: clinical or commercial scale bulk lot(s). QTY of 1 for unit price of $8,609,815. The period of performance remains august 22, 2020 thru august 21, 2021. All
Quick answers
Who was awarded contract 75A50120F33013?
75A50120F33013 was awarded to Glaxosmithkline, LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 1, 2020.
How much is contract 75A50120F33013 worth?
The government has obligated $63,883 on 75A50120F33013.
Is contract 75A50120F33013 an order under another contract?
Yes. 75A50120F33013 is a delivery order under HHSO100201600004I, an indefinite delivery contract, on Pandemic Influenza Preparedness and Response 2016-2021.
Was contract 75A50120F33013 competed?
The extent of competition for 75A50120F33013 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award